

May 24, 2016  
 SymBio Pharmaceuticals Limited  
 Fuminori Yoshida  
 Representative Director  
 President and Chief Executive Officer  
 (Securities Code: 4582)

## Notice concerning the Change of Major Shareholder

SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “the Company”) announced today that the Company’s major shareholder has changed as follows.

1. Date of this change  
 May 16, 2016
  
2. Background to this change  
 The major shareholder of the Company has changed as set out in the large shareholding report submitted by Whiz Partners Inc. as of May 23, 2016.
  
3. Overview of the Company’s current major and largest shareholder
  - (1) Name: Whiz Healthcare Japan 2.0 Investment Limited Partnership
  - (2) Address: Atago Green Hills Mori Tower 36F, 2-5-1, Atago, Minato-ku, Tokyo
  - (3) Business: Investment Management Business
  
4. Voting rights and ownership percentage in respect of the Company before and after said change of the major and largest shareholder

	Number of voting rights (number of shares owned)	Ownership percentage in proportion to the total number of voting rights	Order of large shareholders
Before said change (as of May 11, 2016)	43,105 units (4,310,501 shares)	11.56%	The largest
After said change	35,380 units (3,538,001 shares)	9.49%	The largest

(Notes)

1. The number of shares excluded from the number of the Company’s outstanding shares due to the non-existence of voting rights: 75 shares
2. The number of the Company’s outstanding shares as of May 16, 2016: 37,289,124 shares.

(The number of the Company's outstanding shares as of May 11, 2016:  
37,289,124 shares.)

3. The ownership percentage in proportion to the total number of voting rights is rounded off to the second decimal place.

5. Future outlook

The change of the major and largest shareholder of the Company will not impact the Company's performance or business relationship with other companies.

**[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125